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FIGURE 11: ELSD graphs of NLPs of varying composition  
0 
400 
800 
1200 
0 10 20 
0 
400 
800 
1200 
S
ig
n
a
l 
In
te
n
s
it
y,
 m
V
 
Time (minutes) 
E4-22k 
Lipid 
E4-22k 
Lipid 
MDP 
Area =1.12x107  
=3.08 mg/mL 
Area = 4.78x106  
=10.97 mg/mL 
Area = 2.15x106  
=0.22mg/mL 
Area =1.14x107 
=3.11  mg/mL 
Area = 4.96x106  
= 11.35 mg/mL 
0 
400 
800 
1200 
0 10 20 
MDP 
E4-22k 
Lipid 
MPLA 
Area = 6.45x106  
=0.31mg/mL 
Area = 1.79x107  
=3.19mg/mL 
Area = 4.65x106  
=7.63mg/mL 
Area = 7.99x106  
=0.26mg/mL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
10 : 1 20 : 1  30 : 1  
R
a
ti
o
s
 o
b
ta
in
e
d
 f
ro
m
 E
L
S
D
 Q
u
a
n
ti
fi
c
a
ti
o
n
 
MDP:NLP ratios 
Initial Ratios 
Incorporation Ratio: During Assembly 
Incorporation Ratio: Post Assembly 
FIGURE 12: Comparison of the addition of adjuvants during the 
assembly process vs. after assembly 
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Nanolipoprotein particles (NLPs) are small particles composed of 
lipid and protein. The lipid in the NLP is arranged in a bilayer 
fashion. The protein wraps round the hydrophobic tails which 
allows them to be soluble in aqueous buffers. 
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FIGURE 1 
The different components (lipids, protein and adjuvants) are 
combined with a detergent in a buffered solution. As the 
detergent is removed from the solution by dialysis, the particles 
self-assemble into disk-shaped structures (Figure 2, above). 
Adjuvants are molecules that initiate an immune response, and 
can be added to NLPs during the assembly process or to pre-
assembled particles. The adjuvants used in this study are shown 
below (Figures 4 and 5). 
FIGURE 2 
Reverse phase HPLC separates mixtures based on polarity, in 
this case using a gradient of methanol and isopropanol to 
elute the components off of a column packed with hydrophobic 
resin. Depending on the its affinity to the hydrophobic resin, 
each component will elute off of the column at a characteristic 
solvent ratio, as depicted in the graph above (Figure 10). Each 
peak corresponds to a particular component of the NLP 
mixture. The area of each component peak is directly related 
to its concentration within the sample. Standard curves were 
prepared using known concentrations of purified compounds 
and are shown in the boxes below the chromatogram (Figure 
10). 
The traces above (Figure 11) show data from samples of NLPs 
containing different components. The elution time identifies the 
compound. The integrated peak area is then analyzed using the 
standard curve to determine the concentration of the component 
within the sample. 
Nanolipoprotein particles (NLPs) self-assemble into nanoscale structures that can be used as 
vaccines or drug delivery agents. Due to the nature of the NLPs,  a variety of immune stimulating 
compounds or adjuvants can be readily incorporated into NLPs: a characteristic difficult to 
engineer into most other nanoscale platforms. In light of this, a method for quantifying the 
amount adjuvant actually incorporated into NLPs is a question of high importance. Through the 
use of reverse phase High-Performance Liquid Chromatography (HPLC) and an Evaporative Light 
Scattering Detector (ELSD), standard curves can be constructed by analyzing mixtures of NLP 
components of known concentration, which can then be used to quantify samples of NLPs and 
determine the amount of adjuvant incorporated. After constructing NLPs containing different 
combinations of the adjuvants monophosphoryl lipid A (MPLA) and muramyl dipeptide (MDP), 
they were tested in vitro to determine the intensity of immune response using enzyme-linked 
immunosorbent assays (ELISAs). ELISA results indicate that when both adjuvants are 
incorporated into a single NLP, the amount of cytokine production is significantly increased, 
compared to adjuvants individually incorporated into the NLPs as well as non-NLP formulations of 
the combined adjuvants. Therefore, the NLPs represent an attractive platform for delivering and 
enhancing adjuvant combinations for immunological therapeutics. 
NLPs can be characterized using size exclusion chromatography, 
a technique used to separate the components of a mixture by 
their size. The graphs above (Figures 3-6) show that all NLPs 
elute at approximately 8.5 minutes, regardless of composition. 
When NLPs are analyzed with a spectrophotometer using size-
exclusion chromatography alone, there is little difference 
between NLPs composed of different molecules.  
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FIGURE 13:  IL-6 cytokine response of 
J774 macrophages to adjuvated NLPs 
NLPs can be adjuvated during the assembly process or after 
the NLPs have been formed, depending on the adjuvant.  
However, it is far more efficient to incorporate adjuvants during 
the assembly process, as shown in Figure 12 above. 
Although there are many different types of adjuvants that can be incorporated 
into NLPs, there are many factors to consider in relation to immune response 
that these adjuvant or adjuvant combinations will elicit: the chemical 
characteristics of the adjuvants, the adjuvant-to-NLP ratios, the dose, and the 
combination of different adjuvants. The in vitro results presented here indicate 
that while only MPLA incorporated into NLPs individually elicits a significant 
response, the combination of MDP with MPLA within the NLP further enhances 
cytokine production. It can be concluded that the two adjuvants act in concert, 
especially when incorporated into the NLPs, to increase the potency compared 
to each adjuvant alone.  
Conclusion/Future Research 
The traces above show NLPs analyzed using two methods: UV-Vis and 
ELSD.  In contrast to UV-Vis absorbance measurements, the ELSD can 
detect the components of the NLP that have no intrinsic absorbance (e.g. 
MDP and DOPC lipid) can be visualized. The gain can be changed to 
detect both small and large amounts of material.  
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Through the use of an evaporative light scattering detector 
(ELSD), the different components of the NLP can be detected 
and quantified. After the sample is separated by reverse 
phase HPLC, the sample is nebulized to form tiny droplets. 
The solvent within the resulting droplets is then evaporated 
using a stream of nitrogen gas, leaving behind the solute 
containing the compound of interest. Prior to detection the 
solute passes through an oven to ensure that any residual 
solvent is removed. The solute particles then pass through a 
beam of light, and the amount of light scattered by the solute 
particles is detected by a photomultiplier.  
FIGURE 7: The diagram above shows how the 
amount of solute in the sample is detected. 
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FIGURE 8: The HPLC-ELSD 
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The cartoon above depicts a cell’s response to an 
adjuvant(   ).  The adjuvant can be taken up by the 
cell and cause the cell to produce signals called 
cytokines.  Cytokines then signal other cells, 
producing an immunological response 
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FIGURE 3: Standard NLP 
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FIGURE 4: NLP with MDP 
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FIGURE 5: NLP with MPLA  
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FIGURE 6: NLP with MPLA and MDP 
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FIGURE 9: Detection of NLP components UV-VIS vs. ELSD 
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Two different amounts of 
adjuvanted NLPs were 
used to elicit immune 
responses, measured by 
macrophage production of  
IL-6 (Figure 13,left).  When 
NLPs contain a single 
adjuvant the amount of 
cytokine production is 
either modest (MPLA) or 
below the limit of detection 
(MDP). However, when 
particles are made with a 
combination of MPLA and 
MDP there is a significant 
amount of IL-6 production. 
At the lower dose (0.05 
µg/mL MPLA) there is a 
significant increase in the 
amount of IL-6 produced 
between the adjuvants 
incorporated into the NLP 
versus the adjuvant alone. 
At the higher dose (0.5 
µg/mL MPLA), the strong 
stimulation by MPLA 
appears to mask any 
contribution of the 
relatively low levels of MDP. 
These results are similar to 
the measured production 
of a second cytokine, TNF-α 
(Figure 14). 
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FIGURE 14:  TNF-α cytokine response of 
J774 macrophages to adjuvated NLPs 
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